In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responsesMarcin Kortylewski, Hua Yu, John J. Rossi et al.|Nature Biotechnology|2009Cited by 378
RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34 <sup>+</sup> Cells in Patients Undergoing Transplantation for AIDS-Related LymphomaDavid DiGiusto, John A. Zaia, Amrita Krishnan et al.|Science Translational Medicine|2010Cited by 376
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Cell Reports Medicine|2025Cited by 12
Abstract LB192: MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockadeRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Cancer Research|2023Cited by 1
850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignanciesRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Regular and Young Investigator Award Abstracts|2022Cited by 1